Rheonix and Life Technologies Introduce Molecular Testing Platform
By LabMedica International staff writers Posted on 24 Aug 2014 |
Rheonix, Inc., (Ithaca, NY, USA) solutions, and Life Technologies Corp. (Carlsbad, CA, USA) introduced a molecular testing platform for their Applied Markets business. The development agreement of Rheonix with Life Technologies addresses needs in the clinical diagnostics and food safety markets.
Technology developed by Rheonix for the molecular diagnostics market, including the Rheonix CARD, a disposable cartridge the size of a credit card that can run multiple samples simultaneously without user intervention, and will be supplied by Rheonix to Life Technologies for marketing, sales, and distribution. The partnership will significantly shorten the time necessary for Rheonix to enter the clinical market with its sample-to-result molecular diagnostic instrument.
The instrument and consumable cartridges are components of a molecular detection system specifically designed for the food testing market that will enable laboratories to detect disease-causing organisms, including serotype identification, in a fully automated and highly efficient manner. The new platform is targeted for initial introduction in 2014.
Related Links:
Rheonix, Inc.
Life Technologies Corp.
Technology developed by Rheonix for the molecular diagnostics market, including the Rheonix CARD, a disposable cartridge the size of a credit card that can run multiple samples simultaneously without user intervention, and will be supplied by Rheonix to Life Technologies for marketing, sales, and distribution. The partnership will significantly shorten the time necessary for Rheonix to enter the clinical market with its sample-to-result molecular diagnostic instrument.
The instrument and consumable cartridges are components of a molecular detection system specifically designed for the food testing market that will enable laboratories to detect disease-causing organisms, including serotype identification, in a fully automated and highly efficient manner. The new platform is targeted for initial introduction in 2014.
Related Links:
Rheonix, Inc.
Life Technologies Corp.
Latest Industry News
- Danaher and Johns Hopkins University Collaborate to Improve Neurological Diagnosis
- Beckman Coulter and MeMed Expand Host Immune Response Diagnostics Partnership
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance